Objective: To describe the pharmacokinetics of abacavir 600mg once daily (q.d.) in HIV-1-positive women during pregnancy and postpartum. Design: A nonrandomized, open-label, multicentre, phase-IV study. Methods: HIV-positive pregnant women receiving abacavir 600mg q.d. as part of clinical care were included. Intensive 24-h pharmacokinetic sampling was performed during the third trimester and at least 2 weeks after delivery. Pharmacokinetic parameters were calculated by noncompartmental analysis. Paired cord blood and maternal blood samples were taken at delivery when feasible. Results: A total of 14 women were included in the analysis. Geometric mean ratios (90% confidence intervals) of third trimester versus postpartum were 1.05 (0.92-1.19) for AUC 0-24h and 1.00 (0.83-1.21) for C max. The median (range) ratio of abacavir cord plasma to maternal plasma was 1.0 (0.7-1.0, n=3). Viral load at the third trimester visit was less than 50copies/ml in 13 participants (93%; one unknown). In total, 13 (93%; one unknown) children were tested HIV-negative. Conclusion: The pharmacokinetics of abacavir 600mg q.d. during pregnancy are equivalent to postpartum. No dose adjustments are required during pregnancy and similar antiviral activity is expected.

, , , , , , ,
doi.org/10.1097/QAD.0000000000001046, hdl.handle.net/1765/90555
Erasmus MC: University Medical Center Rotterdam

Schalkwijk, S, Colbers, A, Konopnicki, D, Weizsäcker, K, Moltó, J, Tenorio, C.H, … Burger, D.M. (2016). The pharmacokinetics of abacavir 600mg once daily in HIV-1-positive pregnant women. AIDS, 30(8), 1239–1244. doi:10.1097/QAD.0000000000001046